BEYOND: Explore the ongoing, real-world evidence study2
CABENUVA is the only complete, long-acting regimen for the treatment of HIV.
Identify patients for CABENUVA in your practice
"Some days taking daily oral therapy is fine, but some days it's a challenge."
Jorge—Patient Ambassador
See Jorge’s HIV treatment story
CABENUVA access and acquisition
Get comprehensive support from benefit verification to reimbursement to acquisition to co-pay collection.
Questions to ask your patients about taking daily oral therapy for HIV
“How would you feel if you didn't have to take a daily oral therapy?”
“Would a long-acting regimen be a better fit for you?”
References:
- Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. Lancet HIV. 2023;10(9):E566-E577. doi.org/10.1016/S2352-3018(23)00136-4
- Sinclair G, et al. Clinical outcomes at month 6 after initiation of cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world study (BEYOND). Poster presented at: IDWeek on HIV Treatment; October 15-11, 2023; Boston, MA.
CBRWCNT240003